



THE PLATFORM GROUP

Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014

The Platform Group is negotiating an acquisition in the pharmaceutical platform sector and is considering a bond tap issue

Düsseldorf, 22 August 2025. The Platform Group AG ("TPG", ISIN: DE000A2QEFA1) is currently conducting in-depth discussions regarding the acquisition of three companies that operate platforms in the pharmaceutical sector. TPG has been active in the pharmaceutical sector since 2021 through its stake in ApoNow and plans to significantly expand this area in the future. Corresponding letters of intent were signed in August 2025. The companies to be acquired are based in Germany, Austria, and the Czech Republic. The aim is to conclude the corresponding purchase agreements in September 2025. On completion, TPG's revenue and earnings position would change significantly: the acquisition of the three companies would – after closing – lead to an expected additional annual revenue volume in the low three-digit million-euro range, with an EBITDA margin of 4-6%. The purchase price will be in the double-digit million-euro range.

To implement the above transactions and finance them, TPG will consider a possible increase in the existing corporate bond 2024/2028 (ISIN NO0013256834).

Contact:

Investor Relations

Bjoern Minnier, CFO and Head of IR

ir@the-platform-group.com

Schloss Elbroich | Am Falder 4 | 40589 Düsseldorf | Germany

corporate.the-platform-group.com